NasdaqGS:INSMBiotechs
Why Insmed (INSM) Is Up 5.4% After FDA Approves First Oral NCFB Therapy BRINSUPRI
On August 12, 2025, Insmed Incorporated announced that the U.S. FDA approved BRINSUPRI (brensocatib), the first and only FDA-approved oral therapy for non-cystic fibrosis bronchiectasis in adults and children 12 years and older, with Maxor Specialty Pharmacy later selected as a limited distribution provider.
This approval not only introduces a first-in-class treatment for an underserved patient population but also positions Insmed to potentially establish a new standard of care for...